Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 214 results for "celgene corporation headquarters"

Celgene Corporation to Webcast at Upcoming Investor Conferences

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcast will be ... CNBC, 1 week ago
[x]  

Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial

--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that additional data of exploratory endpoints from the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with ...
 Drugs.com1 month ago Celgene Release: Oral Ozanimod Showed Histologic Improvements In Patients With Ulcerative Colitis In The Phase 2 TOUCHSTONE Trial  BioSpace2 months ago Celgene : Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial  4 Traders2 months ago
[x]  

Agiosand Celgene Establish New Collaboration in MetabolicImmuno-Oncology and Amend Certain Rights from 2010 Agreement

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and Celgene Corporation (NASDAQ:CELG) today announced an agreement creating a new global strategic collaboration focused on metabolic immuno-oncology, an emerging field of cancer research focused on altering ...
 Minyanville1 week ago Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement  PharmaVOICE1 week ago Agios, Celgene Hammer Out $1 Billion+ Metabolic Immuno-Oncology Deal  BioSpace1 week ago CELGENE : Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement  4 Traders1 week ago
[x]  

Triphase Accelerator Corporation Announces Expansion of Collaboration with Celgene in the Development of Marizomib for the Treatment of Gliomas

(GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it is expanding its current collaboration with Celgene Corp. in ...
 4 Traders3 weeks ago
[x]  

Celgene And Juno Announce Exercised Option To Develop And Commercialize CD19-Directed Product Candidates

-- $50 million opt-in payment for CD19 program to Juno -- SUMMIT, N.J. & SEATTLE--( BUSINESS WIRE )--Celgene Corporation (NASDAQ: CELG) and Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that Celgene exercised its option to develop and ...
 BioSpace1 month ago CELGENE : and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-directed Product Candidates  4 Traders1 month ago Celgene and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-directed Product Candidates  TMC Net1 month ago
[x]  

Celgene launches fictional film, Millefeuille, to shed new light on complex psoriasis challenges

BOUDRY, Switzerland--( BUSINESS WIRE )--Celgene announced today the official release of Millefeuille (A Thousand Leaves) , a short, fictional film developed and produced in collaboration with the award-winning Bedrock Multimedia and Turtle Canyon ...
 Business Wire2 weeks ago
[x]  

PIERIS PHARMACEUTICALS : Reports Full-Year 2015 Financial Results and Corporate Update

BOSTON, MA -- (Marketwired) -- 03/22/16 -- Pieris Pharmaceuticals, Inc . (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform, announced today 2015 corporate highlights, a ...
 4 Traders2 months ago Pieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update  Financial Buzz2 months ago
[x]  

Lenvima® (lenvatinib) Now Available in Israel as Important New Treatment for People with Advanced Thyroid Cancer

Comments HATFIELD, England, March 9, 2016 /PRNewswire/ -- FOR ISRAELI AND UK MEDIA ONLY From today, people in Israel with radioactive iodine refractory differentiated thyroid cancer (RAI refractory DTC) will have access to Lenvima® (lenvatinib), ...
 AndhraNews.net3 days ago

VAXIMM Appoints Pharmaceutical Industry Veteran Dr. Jarl Ulf Jungnelius as Chief Medical Officer

DGAP-News: VAXIMM AG / Key word(s): Change of Personnel 2016-05-18 / 09:17 The issuer is solely responsible for the content of this announcement. VAXIMM Appoints Pharmaceutical Industry Veteran Dr. Jarl Ulf Jungnelius as Chief Medical ...
 Yahoo! Finance UK and Ireland1 week ago DGAP-News: VAXIMM Appoints Pharmaceutical Industry Veteran Dr. Jarl Ulf Jungnelius as Chief Medical Officer  Pharmacy Choice1 week ago

Nurix Announces New Appointments to Its Board of Directors

By a News Reporter-Staff News Editor at Biotech Week Nurix, Inc., a private drug discovery company, announced the appointments of David Lacey, M.D., and Perry Karsen to the company's board of directors. In addition, Tim Kutzkey, Ph.D., a partner at ...
 Pharmacy Choice1 week ago Nurix Strengthens Executive Leadership Team  Digital Journal3 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - celgene corporation headquarters
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less